Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Multiple Myeloma 4Recurrence 2Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma 1Leukemia, B-Cell 1Leukemia 1Klatskin Tumor 1Hematologic Neoplasms 1Hematologic Diseases 1Fallopian Tube Neoplasms 1Disease Progression 1Disease 1Cholangiocarcinoma 1Breast Neoplasms 1Blood Protein Disorders 1Bile Duct Neoplasms 1

Interventions

Dexamethasone 808Bortezomib 446Lenalidomide 430Cyclophosphamide 336Melphalan 250Calcium Dobesilate 236daratumumab 217pomalidomide 201carfilzomib 181fludarabine phosphate 131Thalidomide 121fludarabine 118Peripheral Blood Stem Cell Transplantation 117Filgrastim 111ixazomib 85Mycophenolic Acid 85Granulocyte Colony-Stimulating Factor 84Busulfan 83Whole-Body Irradiation 80Tacrolimus 75dexamethasone acetate 74Cyclosporine 67Prednisone 64dexamethasone 21-phosphate 63isatuximab 62elotuzumab 60auricularum 57Antilymphocyte Serum 55belantamab mafodotin 54Etoposide 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Multiple Myeloma × ricolinostat × Clear all
NCT01997840 2025-03-04

ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma

Celgene

Phase 1/2 Terminated
103 enrolled 21 charts
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Plasma Cell

NCT01583283 2022-02-23

Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma

Celgene

Phase 1 Completed
38 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT02189343 2019-11-21

Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma

Celgene

Phase 1 Completed
16 enrolled
Plasma cell

Disease, Multiple Myeloma, Recurrence, Disease Progression

NCT01323751 2017-04-06

ACY-1215

Celgene

Phase 1/2 Completed
120 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡